Trial design should give Dermira’s AD drug a better shot at Phase IIb success
Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at...
Trending:
-
![]()
Roche makes a cautious investment in Ionis’ dAMD drug
-
![]()
ESMO 2018: previewing high-impact, late-breaking abstracts
-
![]()
AbbVie/J&J’s Imbruvica expected to post encouraging PFS rates in CLL
-
![]()
AbbVie’s risankizumab has uptake caveats despite anticipated approvals
-
![]()
Promising therapies in the breast cancer pipeline
-
![]()
The highs and lows of hormone replacement therapy
Most Read
Company A-Z
Latest Content
Flexible Drug Containers for Parenteral Drugs
Self-medication is becoming more popular, driven by cost considerations. Valuable time of healthcare personnel and the high cost of hospital stays are outweighing the costs of treatment drastically.
Europe’s updated guidelines on atopic dermatitis
The latest update to the consensus-based European guidelines for the treatment of atopic dermatitis in adults and children was published in May this year, replacing the previous set of European guidelines published in July 2012.
Why Clinical Trial Equipment Rental Could Transform Your Trial
Industry commentators have claimed that we could be entering a clinical trial equipment rental age.
Trial design should give Dermira’s AD drug a better shot at Phase IIb success
Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at statistical and clinical significance with the exclusion of corticosteroid, a class of steroid hormone, use. The outcome should be able to beat efficacy results of Roche’s previous proof-of-concept (POC) trial that tested lebrikizumab with corticosteroids and only achieved a 20% difference versus placebo, the inactive drug or treatment used in a clinical trial.
Roche makes a cautious investment in Ionis’ dAMD drug
Following up on Roche’s first partnership with Ionis Pharmaceuticals for an early-stage pipeline asset for Huntington’s disease, the two companies have signed a second deal, this time focusing on IONIS-FB-LRx, an antisense pipeline drug using Ionis’ advanced Ligand Conjugated Antisense (LICA) technology, which reduces the production of Factor B, a key protein in the complement innate immune system in a broad range of diseases.
ESMO 2018: previewing high-impact, late-breaking abstracts
The 2018 European Society for Medical Oncology (ESMO) Annual Congress will begin in Munich on October 19, where combination therapies and immuno-oncology strategies feature heavily in the highest impact clinical research abstracts. The best studies at the congress, those considered cutting-edge or practice-changing, will be presented during the three plenary sessions, called Presidential Symposia at ESMO.
AbbVie/J&J’s Imbruvica expected to post encouraging PFS rates in CLL
A 7.5-year follow-up of AbbVie and Johnson & Johnson’s Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) found that the seven-year progression-free survival (PFS) rate is more than 90% for low-risk patients and 30%–40% for high-risk patients.
AbbVie’s risankizumab has uptake caveats despite anticipated approvals
AbbVie’s risankizumab for moderate-to-severe plaque psoriasis will likely face market hurdles despite highly expected regulatory approvals.
UCLH initiates new trial for Alzheimer’s treatment in UK
The NIHR University College London Hospitals (UCLH) Clinical Research Facility in the UK has initiated a clinical trial, DESPIAD, to assess a new treatment called miridesap for Alzheimer’s disease.
Promising therapies in the breast cancer pipeline
Breast cancer is one of the most common forms of cancer worldwide, with approximately 5.4 million cases worldwide in 2016.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
